Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
IDEAYA Biosciences Inc is a biotechnology business based in the US. IDEAYA Biosciences shares (IDYA) are listed on the NASDAQ and all prices are listed in US Dollars. IDEAYA Biosciences employs 75 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$22.01|
|52-week range||$12.01 - $28.00|
|50-day moving average||$25.39|
|200-day moving average||$22.20|
|Wall St. target price||$30.44|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.98|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||-2.48%|
|1 month (2021-09-27)||-16.85%|
|3 months (2021-07-27)||-3.12%|
|6 months (2021-04-27)||5.26%|
|1 year (2020-10-26)||77.50%|
|2 years (2019-10-25)||295.15%|
|3 years (2018-10-23)||N/A|
|5 years (2016-10-23)||N/A|
|Revenue TTM||$35.5 million|
|Gross profit TTM||$-20,160,000|
|Return on assets TTM||-7.42%|
|Return on equity TTM||-14.57%|
|Market capitalisation||$880.2 million|
TTM: trailing 12 months
There are currently 2.6 million IDEAYA Biosciences shares held short by investors – that's known as IDEAYA Biosciences's "short interest". This figure is 31.1% up from 2.0 million last month.
There are a few different ways that this level of interest in shorting IDEAYA Biosciences shares can be evaluated.
IDEAYA Biosciences's "short interest ratio" (SIR) is the quantity of IDEAYA Biosciences shares currently shorted divided by the average quantity of IDEAYA Biosciences shares traded daily (recently around 425065.19607843). IDEAYA Biosciences's SIR currently stands at 6.12. In other words for every 100,000 IDEAYA Biosciences shares traded daily on the market, roughly 6120 shares are currently held short.
However IDEAYA Biosciences's short interest can also be evaluated against the total number of IDEAYA Biosciences shares, or, against the total number of tradable IDEAYA Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IDEAYA Biosciences's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 IDEAYA Biosciences shares in existence, roughly 70 shares are currently held short) or 0.0757% of the tradable shares (for every 100,000 tradable IDEAYA Biosciences shares, roughly 76 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against IDEAYA Biosciences.
Find out more about how you can short IDEAYA Biosciences stock.
We're not expecting IDEAYA Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, IDEAYA Biosciences's shares have ranged in value from as little as $12.01 up to $28. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IDEAYA Biosciences's is 1.762. This would suggest that IDEAYA Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
IDEAYA Biosciences, Inc. , a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients with solid tumors having MTAP deletions; PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.